Imagin Medical Inc. IMEXF Archives - Page 4 of 6

MondayMar 15, 2021 12:16 pm

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Revolutionary Technology a Cost Saver for Hospitals and Patients

White light cystoscopy (“WLC”) is the most commonly used procedure to detect non-muscle invasive bladder cancer (“NMIBC”) Despite its prevalence, WLC is not the most effective method and contributes to a high bladder cancer recurrence rate Blue light cystoscopy (“BLC”) is a more recent and highly effective method, but the high cost of equipment and skill level has impeded its uptake among hospitals Imagin Medical believes the i/Blue(TM) Imaging System , which displays white and blue light images side by side, will address these issues It eliminates the need to purchase new cystoscopes. The i/Blue System’s dual-view camera head can…

FridayMar 12, 2021 1:04 pm

QualityStocksNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Solution Solves Cystoscopy Challenges

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, has developed a product that deals with the challenges associated with both blue light and white light cystoscopies. Clinical data support the value of blue light cystoscopy in detecting bladder cancer. Despite this fact, “the technology is used in less than 10% of such procedures because of the high cost of equipment.” Secondly, white light cystoscopy is ineffective in detecting all tumors. This poses a challenge as surgeons have to switch “back and forth between white light and blue light images to locate and resect tumors. And that’s where Imagin…

MondayMar 08, 2021 10:49 am

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Takes Bladder Cancer Battle to Next Level

Imagin Medical has developed a technology, currently entering the manufacturing stage, which it believes will revolutionize bladder cancer surgical imaging The company’s technology, the i/Blue Imaging System, can display blue and white light images of the bladder side-by-side simultaneously, allowing surgeons greater ability to detect and remove tumors Imagin has raised a $2.165 million convertible note offering to fund the company during the manufacturing phase of its surgical imaging system as well as the U.S. Food and Drug Administration (“FDA”) approval process Bladder cancer is one of the most prevalent cancers in the United States, particularly in men, and is…

FridayMar 05, 2021 1:36 pm

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Bringing Effective Solutions to Vast Market

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is engaged in establishing a new standard for the visualization of cancer during minimally invasive surgeries (“MIS”). The company is currently focused on bladder cancer, the most expensive cancer to treat due to a high 50% recurrence rate that leaves approximately 600,000 U.S. patients living in fear that their cancer will return. Imagin Medical’s i/Blue(TM) Imaging System has the ability to overcome limitations of today’s white and blue light cystoscopy procedures. The innovative technology enables surgeons to see real-time white and blue light images on the screen simultaneously during a…

WednesdayMar 03, 2021 12:25 pm

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Reimagines Technology to Create Better Cancer Outcomes

Archaic technology contributes to dismal recurrence rate in bladder cancer Imagin Medical revolutionizes the way surgeons can visualize cancer to better identify, and remove during surgery There is potential to extend this technology to virtually other endoscopic procedures The battle against cancer is too often set back by crushing blows of recurrence. The disease is insidious. If every single malignant cell of a tumor is not completely removed, it can rebound and attack again. Nowhere is this dismal recurrence more prevalent than in bladder cancer. Caught early, bladder cancer stands a better chance of being successfully treated through surgery and…

FridayFeb 26, 2021 12:12 pm

Better Cancer Outcomes Possible with Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) Technology

Imagin Medical Inc.’s patented i/Blue System revolutionizes the way surgeons are able to visualize the bladder and identify cancers during surgery The breakthrough technology of Imagin Medical’s i/Blue Imaging System rectifies the limitations of both white and blue light cystoscopies Bladder cystoscopies first target - multiple other endoscopic procedures planned Science and technology have continued to make striking advancements in cancer therapeutics and treatment protocols, improving upon on past successes and creating better outcomes for cancer patients. A prime example is an exciting new development in visualizing cancer during minimally invasive surgeries. Surgical imaging company Imagin Medical (CSE: IME) (OTCQB:…

ThursdayFeb 25, 2021 3:17 pm

QualityStocksNewsBreaks – Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) i/Blue Imaging(TM) Technology Holds Potential Across Multiple Endoscopic Procedures

Imagin Medical (CSE: IME) (OTCQB: IMEXF), a surgical imaging company, is focused on changing the standards of visualizing cancer during minimally invasive procedures. The company’s innovative technology has the potential to revolutionize the current standard of care for bladder cancer patients. Imagin Medical’s i/Blue Imaging(TM) System is based on advanced optics and light sensors and uses patented ultrasensitive imaging technology. The state-of-the-art control unit features a dual-wavelength light source, two-channel camera control and data recorder. Simultaneous white and blue light illumination of the bladder allows for side-to-side image monitoring and better visualization of tumors and margins. A recent article discussing…

MondayFeb 22, 2021 11:56 am

Convertible Note Progress Brings Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Closer to Commercialization of New Surgical Tech

Imagin Medical Inc. announced that it has now raised $2.165 million of the recent its convertible note offering The closing of the latest funding tranche will support the company’s progress toward the commercialization of its revolutionary bladder cancer visualization technology once final FDA approval is granted With better viewing options, the technology is designed to make it easier for surgeons to detect the full parameters of bladder tumors and remove them more completely Bladder cancer is one of the most prevalent cancers in the United States, particularly in men The technological improvement of these surgical procedures can provide an attractive…

ThursdayFeb 18, 2021 9:48 am

QualityStocksNewsBreaks – Imagin Medical Inc. (CSE: IME) (OTC: IMEXF) Announces Closing of 2nd Tranche of Convertible Note Offering

Imagin Medical (CSE: IME) (OTC: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive procedures, today announced that, further to its press releases of Oct. 22 and Nov. 10, 2020, it has closed the second tranche in the amount of US$1,415,500 of the convertible note offering. According to the update, a total convertible note amount of $2,165,500 has been raised to date. All securities issued in connection with the offering will be subject to a four-month statutory hold period plus one day from the date of issuance in accordance with…

ThursdayFeb 18, 2021 9:40 am

Imagin Medical Inc.’s (CSE: IME) (OTCQB: IMEXF) Improving the Odds in Fighting Bladder Cancers

Imagin Medical Inc. is a surgical imaging company helping to advance the use of blue light cystoscopy (“BLC”) in battling bladder cancer and reducing costs associated with these procedures Bladder cancer is the sixth most prevalent cancer in the United States, and the third most common in men, yet the most expensive to treat While early-stage cancer intervention involves illuminating the bladder with white light – the light that can be seen by the human eye - to visualize and resect tumors, historical use of white light has resulted in incomplete tumor removal and a greater than 50% recurrence rate…

Site Search

Company Search

Tag: Imagin Medical Inc. IMEXF